{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:18:54Z","timestamp":1758845934453,"version":"3.44.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ucl.2022.09.011","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T16:55:22Z","timestamp":1669049722000},"page":"115-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted Molecular Imaging as a Biomarker in Urologic Oncology"],"prefix":"10.1016","volume":"50","author":[{"given":"Arvin","family":"Haj-Mirzaian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umar","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedram","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.eururo.2016.10.008","article-title":"Global burden of urologic cancers, 1990\u20132013","volume":"71","author":"Dy","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2022.09.011_bib2","first-page":"801","article-title":"PET imaging for prostate cancer","volume":"59","author":"Savir-Baruch","year":"2021","journal-title":"Radiologic Clin"},{"issue":"2","key":"10.1016\/j.ucl.2022.09.011_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.biotechadv.2016.11.009","article-title":"Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools","volume":"35","author":"Sharma","year":"2017","journal-title":"Biotechnol Adv"},{"issue":"4","key":"10.1016\/j.ucl.2022.09.011_bib4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s00259-014-2982-5","article-title":"Imaging biomarkers in prostate cancer: role of PET\/CT and MRI","volume":"42","author":"Picchio","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1148\/rg.2016150059","article-title":"Molecular imaging of prostate cancer","volume":"36","author":"Wibmer","year":"2016","journal-title":"Radiographics"},{"issue":"4","key":"10.1016\/j.ucl.2022.09.011_bib6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","article-title":"Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique","volume":"50","author":"Mhawech-Fauceglia","year":"2007","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of 68 Ga-PSMA-11 and 18 F-DCFPyL normal-organ biodistribution","volume":"19","author":"Ferreira","year":"2019","journal-title":"Cancer Imaging"},{"issue":"5","key":"10.1016\/j.ucl.2022.09.011_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","article-title":"68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: a systematic review and meta-analysis","volume":"4","author":"von Eyben","year":"2018","journal-title":"Eur Urol focus"},{"issue":"6","key":"10.1016\/j.ucl.2022.09.011_bib9","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","article-title":"68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-020-01675-4","article-title":"Can 68Ga-prostate specific membrane antigen positron emission tomography\/computerized tomography provide an accurate lymph node staging for patients with medium\/high risk prostate cancer? A diagnostic meta-analysis","volume":"15","author":"Peng","year":"2020","journal-title":"Radiat Oncol"},{"issue":"15","key":"10.1016\/j.ucl.2022.09.011_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025417","article-title":"The meta-analysis of the effect of 68Ga-PSMA-PET\/CT diagnosis of prostatic cancer compared with bone scan","volume":"100","author":"Zhao","year":"2021","journal-title":"Medicine"},{"issue":"21","key":"10.1016\/j.ucl.2022.09.011_bib12","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.3390\/cancers13215360","article-title":"Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends","volume":"13","author":"Manafi-Farid","year":"2021","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.ucl.2022.09.011_bib13","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib14","first-page":"52","article-title":"A\u00a0phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2022.09.011_bib15","doi-asserted-by":"crossref","first-page":"649171","DOI":"10.3389\/fonc.2021.649171","article-title":"Performance of 18F-DCFPyL PET\/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/diagnostics11030552","article-title":"Diagnostic role of 18F-PSMA-1007 PET\/CT in prostate cancer staging: a systematic review","volume":"11","author":"Awenat","year":"2021","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.ucl.2022.09.011_bib17","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.ucl.2022.09.011_bib18","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0090-4295(99)00314-3","article-title":"Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer","volume":"54","author":"Manyak","year":"1999","journal-title":"Urology"},{"issue":"6 suppl","key":"10.1016\/j.ucl.2022.09.011_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1200\/jco.2013.31.6_suppl.31","article-title":"Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC)","volume":"31","author":"Morris","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib20","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2967\/jnumed.120.257758","article-title":"A\u00a0Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor\u2013Positive Prostate Cancer","volume":"63","author":"Bratanovic","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"19","key":"10.1016\/j.ucl.2022.09.011_bib21","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-12-3490","article-title":"In\u00a0vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548","volume":"19","author":"K\u00e4hk\u00f6nen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ucl.2022.09.011_bib22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.euo.2018.08.011","article-title":"Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography\/computed tomography imaging of newly diagnosed prostate cancer","volume":"2","author":"Touijer","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"2 suppl","key":"10.1016\/j.ucl.2022.09.011_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1200\/jco.2016.34.2_suppl.80","article-title":"Detection of prostate cancer with the [68Ga]-labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy","volume":"34","author":"Stephens","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"15 suppl","key":"10.1016\/j.ucl.2022.09.011_bib24","doi-asserted-by":"crossref","first-page":"e17536","DOI":"10.1200\/JCO.2020.38.15_suppl.e17536","article-title":"A prospective study of 68Ga-RM2 PET\/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging","volume":"38","author":"Baratto","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.ucl.2022.09.011_bib25","first-page":"713","article-title":"Detection of additional primary neoplasms on 18F-Fluciclovine PET\/CT in patients with primary prostate cancer","volume":"63","author":"Parihar","year":"2021","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.ucl.2022.09.011_bib26","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3390\/cancers11091348","article-title":"18F-Facbc in prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Laudicella","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib27","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1148\/rg.2019180139","article-title":"Review of 18F-fluciclovine PET for detection of recurrent prostate cancer","volume":"39","author":"Gusman","year":"2019","journal-title":"Radiographics"},{"issue":"9","key":"10.1016\/j.ucl.2022.09.011_bib28","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2022.09.011_bib29","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1148\/rg.2017170035","article-title":"Clinical PET imaging in prostate cancer","volume":"37","author":"Wallitt","year":"2017","journal-title":"Radiographics"},{"issue":"6","key":"10.1016\/j.ucl.2022.09.011_bib30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1053\/j.semnuclmed.2016.07.004","article-title":"Is There Use for FDG-PET in Prostate Cancer?","volume":"46","author":"Jadvar","year":"2016","journal-title":"Semin Nucl Med"},{"issue":"06","key":"10.1016\/j.ucl.2022.09.011_bib31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3413\/Nukmed-0668-14-05","article-title":"Incidental uptake of 18F-fluorodeoxyglucose in the prostate gland","volume":"53","author":"Bertagna","year":"2014","journal-title":"Nuklearmedizin-NuclearMedicine."},{"key":"10.1016\/j.ucl.2022.09.011_bib32","doi-asserted-by":"crossref","first-page":"683793","DOI":"10.3389\/fonc.2021.683793","article-title":"The evolving role of 18F-FDG PET\/CT in diagnosis and prognosis prediction in progressive prostate cancer","volume":"11","author":"Shen","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2022.09.011_bib33","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41416-020-01224-6","article-title":"The use of hyperpolarised 13C-MRI in clinical body imaging to probe cancer metabolism","volume":"124","author":"Woitek","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib34","first-page":"1","article-title":"Hyperpolarised 13C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer","volume":"13","author":"Sushentsev","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ucl.2022.09.011_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41391-019-0180-z","article-title":"Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study","volume":"23","author":"Chen","year":"2020","journal-title":"Prostate Cancer prostatic Dis"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.110.077941","article-title":"Prostate cancer: PET with 18F-FDG, 18F-or 11C-acetate, and 18F-or 11C-choline","volume":"52","author":"Jadvar","year":"2011","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.ucl.2022.09.011_bib37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40336-013-0016-0","article-title":"Comparative studies of radiolabeled choline positron emission tomography, histology of primary tumor and other imaging modalities in prostate cancer: a systematic review and meta-analysis","volume":"1","author":"Evangelista","year":"2013","journal-title":"Clin Translational Imaging"},{"issue":"11","key":"10.1016\/j.ucl.2022.09.011_bib38","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1007\/s00259-002-0885-3","article-title":"Accumulation of [11C] acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer","volume":"29","author":"Kato","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.ucl.2022.09.011_bib39","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/bju.12279","article-title":"Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature","volume":"112","author":"Mohsen","year":"2013","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ucl.2022.09.011_bib40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2967\/jnumed.112.111153","article-title":"11C-acetate PET\/CT before radical prostatectomy: nodal staging and treatment failure prediction","volume":"54","author":"Haseebuddin","year":"2013","journal-title":"J\u00a0Nucl Med"},{"issue":"12","key":"10.1016\/j.ucl.2022.09.011_bib41","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.21873\/anticanres.11246","article-title":"11C-acetate-PET\/CT compared to 99mTc-HDP bone Scintigraphy in primary staging of high-risk prostate cancer","volume":"36","author":"Strandberg","year":"2016","journal-title":"Anticancer Res"},{"issue":"Supplement 3","key":"10.1016\/j.ucl.2022.09.011_bib42","doi-asserted-by":"crossref","first-page":"55S","DOI":"10.2967\/jnumed.115.169730","article-title":"Evaluation of prostate cancer bone metastases with 18F-NaF and 18F-fluorocholine PET\/CT","volume":"57","author":"Beheshti","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.ucl.2022.09.011_bib43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12149-019-01343-y","article-title":"18F-NaF-PET\/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies","volume":"33","author":"Sheikhbahaei","year":"2019","journal-title":"Ann Nucl Med"},{"issue":"21","key":"10.1016\/j.ucl.2022.09.011_bib44","first-page":"4909","article-title":"Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review","volume":"10","author":"Gauth\u00e9","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib45","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1148\/radiol.13130625","article-title":"Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival","volume":"271","author":"Vargas","year":"2014","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib46","first-page":"366","article-title":"Tumor localization of 16\u03b2-18F-fluoro-5\u03b1-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer","volume":"45","author":"Larson","year":"2004","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00259-005-1764-5","article-title":"Positron tomographic assessment of androgen receptors in prostatic carcinoma","volume":"32","author":"Dehdashti","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.ucl.2022.09.011_bib48","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.7150\/thno.12956","article-title":"First-in-human uPAR PET: imaging of cancer aggressiveness","volume":"5","author":"Persson","year":"2015","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2967\/jnumed.120.248120","article-title":"Urokinase-type plasminogen activator receptor (uPAR) PET\/MRI of prostate cancer for noninvasive evaluation of aggressiveness: comparison with Gleason score in a prospective phase 2 clinical trial","volume":"62","author":"Fosb\u00f8l","year":"2021","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.ucl.2022.09.011_bib50","first-page":"1655","article-title":"Prostatic carcinoma cell migration via \u03b1v\u03b23integrin is modulated by a focal adhesion kinase pathway","volume":"59","author":"Zheng","year":"1999","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.ucl.2022.09.011_bib51","doi-asserted-by":"crossref","first-page":"28151","DOI":"10.18632\/oncotarget.8611","article-title":"Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET","volume":"7","author":"Beer","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ucl.2022.09.011_bib52","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41581-021-00440-4","article-title":"Non-invasive molecular imaging of kidney diseases","volume":"17","author":"Klinkhammer","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2010.03.015","article-title":"Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy","volume":"58","author":"Stillebroer","year":"2010","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MOU.0000000000000872","article-title":"Targeted PET\/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab","volume":"31","author":"van Oostenbrugge","year":"2021","journal-title":"Curr Opin Urol"},{"issue":"4","key":"10.1016\/j.ucl.2022.09.011_bib55","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(07)70044-X","article-title":"Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial","volume":"8","author":"Divgi","year":"2007","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2022.09.011_bib56","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1007\/s00259-019-04613-z","article-title":"Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab","volume":"47","author":"van Oostenbrugge","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib57","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2018.04.026","article-title":"Positron emission tomography\/computed tomography with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion","volume":"74","author":"Hekman","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00261-015-0599-1","article-title":"PET\/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study","volume":"41","author":"Turkbey","year":"2016","journal-title":"Abdom Radiol"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5510-y","article-title":"Early assessment with 18 F-2-fluoro-2-deoxyglucose positron emission tomography\/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab","volume":"19","author":"Tabei","year":"2019","journal-title":"BMC cancer"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib60","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1102\/1470-7330.2012.0042","article-title":"Meta-analysis of the diagnostic performance of [18F] FDG-PET and PET\/CT in renal cell carcinoma","volume":"12","author":"Wang","year":"2012","journal-title":"Cancer Imaging"},{"issue":"5","key":"10.1016\/j.ucl.2022.09.011_bib61","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1097\/RLU.0000000000001612","article-title":"Prognostic value of pretreatment metabolic tumor volume and total lesion glycolysis using 18F-FDG PET\/CT in patients with metastatic renal cell carcinoma treated with anti\u2013vascular endothelial growth factor\u2013targeted agents","volume":"42","author":"Hwang","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1016\/j.ucl.2022.09.011_bib62","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12149-015-1017-z","article-title":"Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET\/CT","volume":"29","author":"Rowe","year":"2015","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib63","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11307-018-1271-2","article-title":"Inconsistent detection of sites of metastatic non-clear cell renal cell carcinoma with PSMA-targeted [18F] DCFPyL PET\/CT","volume":"21","author":"Yin","year":"2019","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib64","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00259-016-3360-2","article-title":"Diagnostic potential of PET\/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience","volume":"44","author":"Sawicki","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"15","key":"10.1016\/j.ucl.2022.09.011_bib65","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/cncr.33554","article-title":"Metabolic imaging with hyperpolarized 13C pyruvate magnetic resonance imaging in patients with renal tumors\u2014Initial experience","volume":"127","author":"Tang","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2022.09.011_bib66","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/cancers14020335","article-title":"Hyperpolarized 13C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma\u2014A Proof of Principle Study","volume":"14","author":"Ursprung","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ucl.2022.09.011_bib67","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12149-018-1287-3","article-title":"Diagnostic performance of 11C-choline PET\/CT and FDG PET\/CT for staging and restaging of renal cell cancer","volume":"32","author":"Nakanishi","year":"2018","journal-title":"Ann Nucl Med"},{"issue":"24","key":"10.1016\/j.ucl.2022.09.011_bib68","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1158\/1078-0432.CCR-11-1677","article-title":"Pharmacodynamic study using FLT PET\/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate","volume":"17","author":"Liu","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40644-015-0049-x","article-title":"FDG and FLT-PET for early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma","volume":"15","author":"Horn","year":"2015","journal-title":"Cancer Imaging"},{"issue":"10","key":"10.1016\/j.ucl.2022.09.011_bib70","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdv289","article-title":"Prospective study evaluating the relative sensitivity of 18F-NaF PET\/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design","volume":"26","author":"Gerety","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2022.09.011_bib71","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2967\/jnumed.110.078030","article-title":"111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib","volume":"51","author":"Desar","year":"2010","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.ucl.2022.09.011_bib72","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2967\/jnumed.116.183475","article-title":"89Zr-bevacizumab PET: potential early indicator of everolimus efficacy in patients with metastatic renal cell carcinoma","volume":"58","author":"van Es","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib73","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2967\/jnumed.114.149021","article-title":"18F-FPRGD2 PET\/CT imaging of integrin \u03b1v\u03b23 in renal carcinomas: correlation with histopathology","volume":"56","author":"Withofs","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.ucl.2022.09.011_bib74","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00259-014-2791-x","article-title":"[18F] Fluciclatide in the in\u00a0vivo evaluation of human melanoma and renal tumors expressing \u03b1v\u03b23 and \u03b1v\u03b25 integrins","volume":"41","author":"Mena","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.ucl.2022.09.011_bib75","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00345-016-1772-z","article-title":"The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis","volume":"34","author":"Soubra","year":"2016","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2022.09.011_bib76","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00345-018-2439-8","article-title":"Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis","volume":"37","author":"Crozier","year":"2019","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000488200","article-title":"Diagnostic accuracy of F-18 FDG PET\/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis","volume":"95","author":"Ha","year":"2018","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.ucl.2022.09.011_bib78","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clgc.2018.05.008","article-title":"FDG-PET\/CT for assessing the response to neoadjuvant chemotherapy in bladder cancer patients","volume":"16","author":"Soubra","year":"2018","journal-title":"Clin Genitourinary Cancer"},{"issue":"9","key":"10.1016\/j.ucl.2022.09.011_bib79","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s00261-017-1443-6","article-title":"Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study","volume":"43","author":"Zattoni","year":"2018","journal-title":"Abdom Radiol"},{"issue":"3","key":"10.1016\/j.ucl.2022.09.011_bib80","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00345-017-2168-4","article-title":"Diagnostic accuracy of C-11 choline and C-11 acetate for lymph node staging in patients with bladder cancer: a systematic review and meta-analysis","volume":"36","author":"Kim","year":"2018","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2022.09.011_bib81","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11307-011-0488-0","article-title":"Initial results with 11C-acetate positron emission tomography\/computed tomography (PET\/CT) in the staging of urinary bladder cancer","volume":"14","author":"Sch\u00f6der","year":"2012","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.ucl.2022.09.011_bib82","doi-asserted-by":"crossref","first-page":"852681","DOI":"10.1155\/2014\/852681","article-title":"Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis","volume":"2014","author":"Treglia","year":"2014","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.ucl.2022.09.011_bib83","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1007\/s10147-015-0817-4","article-title":"Fluorodeoxyglucose positron emission tomography\/computed tomography for diagnosis of upper urinary tract urothelial carcinoma","volume":"20","author":"Asai","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2022.09.011_bib84","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000381269","article-title":"Clinical value of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in upper tract urothelial carcinoma: impact on detection of metastases and patient management","volume":"96","author":"Tanaka","year":"2016","journal-title":"Urologia Internationalis"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014322000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014322000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:56:17Z","timestamp":1758808577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014322000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0094014322000714"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2022.09.011","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Molecular Imaging as a Biomarker in Urologic Oncology","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2022.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}